GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tandem Diabetes Care Inc (NAS:TNDM) » Definitions » Altman Z-Score

TNDM (Tandem Diabetes Care) Altman Z-Score : 1.36 (As of Dec. 14, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Tandem Diabetes Care Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of 1.45 is in distress zone. This implies bankruptcy possibility in the next two years.

Tandem Diabetes Care has a Altman Z-Score of 1.36, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Tandem Diabetes Care's Altman Z-Score or its related term are showing as below:

TNDM' s Altman Z-Score Range Over the Past 10 Years
Min: -8.25   Med: 1.83   Max: 19.49
Current: 1.45

During the past 13 years, Tandem Diabetes Care's highest Altman Z-Score was 19.49. The lowest was -8.25. And the median was 1.83.


Tandem Diabetes Care Altman Z-Score Historical Data

The historical data trend for Tandem Diabetes Care's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tandem Diabetes Care Altman Z-Score Chart

Tandem Diabetes Care Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.03 10.41 12.98 3.13 1.17

Tandem Diabetes Care Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.78 1.17 1.55 1.76 1.89

Competitive Comparison of Tandem Diabetes Care's Altman Z-Score

For the Medical Devices subindustry, Tandem Diabetes Care's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tandem Diabetes Care's Altman Z-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Tandem Diabetes Care's Altman Z-Score falls into.



Tandem Diabetes Care Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Tandem Diabetes Care's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.5153+1.4*-1.0949+3.3*-0.1224+0.6*2.9791+1.0*0.8921
=1.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Sep. 2024:
Total Assets was $957.7 Mil.
Total Current Assets was $752.8 Mil.
Total Current Liabilities was $259.3 Mil.
Retained Earnings was $-1,048.6 Mil.
Pre-Tax Income was -22.614 + -29.743 + -39.529 + -31.31 = $-123.2 Mil.
Interest Expense was -1.865 + -1.793 + -1.145 + -1.197 = $-6.0 Mil.
Revenue was 243.971 + 221.91 + 191.674 + 196.796 = $854.4 Mil.
Market Cap (Today) was $2,145.0 Mil.
Total Liabilities was $720.0 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(752.826 - 259.276)/957.73
=0.5153

X2=Retained Earnings/Total Assets
=-1048.58/957.73
=-1.0949

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-123.196 - -6)/957.73
=-0.1224

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=2144.996/720.02
=2.9791

X5=Revenue/Total Assets
=854.351/957.73
=0.8921

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Tandem Diabetes Care has a Altman Z-Score of 1.36 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Tandem Diabetes Care  (NAS:TNDM) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Tandem Diabetes Care Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Tandem Diabetes Care's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Tandem Diabetes Care Business Description

Traded in Other Exchanges
Address
12400 High Bluff Drive, San Diego, CA, USA, 92130
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Executives
Kim D Blickenstaff director, officer: PRESIDENT AND CEO C/O MEDIVATION, INC., 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94105
Dick Allen director 11045 ROSELLE STREET, SAN DIEGO CA 92121
Shannon Marie Hansen officer: SVP & General Counsel C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Leigh Vosseller officer: Senior Vice President and CFO C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Kathleen Mcgroddy-goetz director C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Peyton R Howell director C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
David B Berger officer: GENERAL COUNSEL 11045 ROSELLE STREET, SAN DIEGO CA 92121
Malagueira Joao Paulo Falcao director C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Myoungil Cha director C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
John F Sheridan officer: EXECUTIVE VP AND COO C/O TANDEM DIABETES CARE, INC., 11045 ROSELLE STREET, SAN DIEGO CA 92121
Christopher J Twomey director 4767 NEXUS CENTRE DRIVE, SAN DIEGO CA 92121
Rebecca B Robertson director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
James Leal officer: SVP, Operations C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Elizabeth Anne Gasser officer: EVP, Chief Strategy Officer C/O TANDEM DIABETES CARE, INC., 11075 ROSELLE STREET, SAN DIEGO CA 92121
Susan Morrison officer: CAO 11045 ROSELLE STREET, SAN DIEGO CA 92121